Literature DB >> 23797472

STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

K A Dorritie1, J A McCubrey2, D E Johnson3.   

Abstract

Signal transducer and activator of transcription (STAT) proteins comprise a family of transcription factors that are activated by cytokines, hormones and growth factors. The activation of STAT proteins plays a key role in the production of mature hematopoietic cells via effects on cellular proliferation, survival and lineage-specific differentiation. Emerging evidence also demonstrates frequent, constitutive activation of STATs in primary leukemia specimens. Moreover, roles for STATs in promoting leukemia development have been delineated in numerous preclinical studies. This review summarizes our current understanding of STAT protein involvement in normal hematopoiesis and leukemogenesis, as well as recent advances in the development and testing of novel STAT inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797472     DOI: 10.1038/leu.2013.192

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  137 in total

1.  Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia.

Authors:  Anna Brady; Sarah Gibson; Lisa Rybicki; Eric Hsi; Yogen Saunthararajah; Mikkael A Sekeres; Ramon Tiu; Edward Copelan; Matt Kalaycio; Ronald Sobecks; Jennifer Bates; Anjali S Advani
Journal:  Eur J Haematol       Date:  2012-07-26       Impact factor: 2.997

2.  Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells.

Authors:  K Shimozaki; K Nakajima; T Hirano; S Nagata
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

3.  Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)

Authors:  F Pane; F Frigeri; M Sindona; L Luciano; F Ferrara; R Cimino; G Meloni; G Saglio; F Salvatore; B Rotoli
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

4.  The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.

Authors:  D W Sternberg; M H Tomasson; M Carroll; D P Curley; G Barker; M Caprio; A Wilbanks; A Kazlauskas; D G Gilliland
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

5.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.

Authors:  Hui Song; Renxiao Wang; Shaomeng Wang; Jiayuh Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

6.  Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.

Authors:  R M Weber-Nordt; C Egen; J Wehinger; W Ludwig; V Gouilleux-Gruart; R Mertelsmann; J Finke
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

7.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.

Authors:  Sergio Gutiérrez-Castellanos; Miguel Cruz; Laura Rabelo; Rocio Godínez; Elba Reyes-Maldonado; Carlos Riebeling-Navarro
Journal:  Eur J Haematol       Date:  2004-04       Impact factor: 2.997

9.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity.

Authors:  Thomas Welte; Samuel S M Zhang; Tian Wang; Zhiyuan Zhang; David G T Hesslein; Zhinan Yin; Arihiro Kano; Yoshiki Iwamoto; En Li; Joseph E Craft; Alfred L M Bothwell; Erol Fikrig; Pandelakis A Koni; Richard A Flavell; Xin-Yuan Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

Review 10.  The role of signal transducer and activator of transcription factors in leukemogenesis.

Authors:  David W Sternberg; D Gary Gilliland
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

View more
  21 in total

Review 1.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

Review 2.  Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia.

Authors:  Mehrdad Hefazi; Mark R Litzow
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

3.  Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome.

Authors:  Hyun Don Yun; Marie Lue Antony; Michael A Linden; Klara E Noble-Orcutt; Craig E Eckfeldt; Celalettin Ustun; Andrew C Nelson; Zohar Sachs
Journal:  Leuk Res       Date:  2020-06-11       Impact factor: 3.156

Review 4.  Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology.

Authors:  Carlota Recio; Borja Guerra; Miguel Guerra-Rodríguez; Haidée Aranda-Tavío; Patricia Martín-Rodríguez; Mercedes de Mirecki-Garrido; Yeray Brito-Casillas; José M García-Castellano; Ana Estévez-Braun; Leandro Fernández-Pérez
Journal:  Oncogene       Date:  2019-02-19       Impact factor: 9.867

Review 5.  T-cell acute lymphoblastic leukemia.

Authors:  Elizabeth A Raetz; David T Teachey
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 6.  Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).

Authors:  Andrew Dunbar; Abbas Nazir; Ross Levine
Journal:  Curr Protoc Pharmacol       Date:  2017-06-22

Review 7.  Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Authors:  Sarah D Cramer; Peter D Aplan; Scott K Durum
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113

Review 8.  Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors.

Authors:  Lisa N Heppler; David A Frank
Journal:  Trends Cancer       Date:  2017-11-10

9.  JAK inhibition in early-onset somatic, nonclonal STAT5B gain-of-function disease.

Authors:  Rachel Eisenberg; Melissa D Gans; Timothy Ronan Leahy; Florian Gothe; Candice Perry; Mark Raffeld; Liqiang Xi; Sarah Blackstone; Chi Ma; Sophie Hambleton; Joshua D Milner
Journal:  J Allergy Clin Immunol Pract       Date:  2020-12-05

Review 10.  Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia.

Authors:  Angelika Berger; Veronika Sexl; Peter Valent; Richard Moriggl
Journal:  Oncotarget       Date:  2014-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.